Evidence map›Paper›PMID 40071070›Full record

ArticleSovremennye tekhnologii v meditsine2025

Migration of Regulatory T Cells to the Peritumor Microenvironment of Experimental Glioblastoma.

E P Yanysheva, P A Melnikov, D A Chudakova, M V Shirmanova, V P Baklaushev, G M Yusubalieva

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Sovremennye tekhnologii v meditsine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

E P YanyshevaJunior Researcher, Laboratory of Solid Tumor Immunotherapy; Federal Center of Brain Research and Neurotechnologies of the Federal Medical Biological Agency of Russia, 1, Bldg. 10, Ostrovityanova St., Moscow, 117513, Russia; Junior Researcher, Laboratory of Cell Technologies; Federal Scientific and Clinical Center for Specialized Types of Medical Care and Medical Technologies of the Federal Medical Biological Agency of Russia, 28 Orekhovy Blvd., Moscow, 115682, Russia.
P A MelnikovPhD, Researcher, Laboratory of Neurobiology; Serbsky Federal Medical Research Centre of Psychiatry and Narcology, 23 Kropotkinsky Lane, Moscow, 119034, Russia.
D A ChudakovaPhD, Senior Researcher, Laboratory of Neuroregeneration; Federal Center of Brain Research and Neurotechnologies of the Federal Medical Biological Agency of Russia, 1, Bldg. 10, Ostrovityanova St., Moscow, 117513, Russia.
M V ShirmanovaPhD, Deputy Director for Science, Research Institute of Experimental Oncology and Biomedical Technologies; Privolzhsky Research Medical University, 10/1 Minin and Pozharsky Square, Nizhny Novgorod, 603005, Russia.
V P BaklaushevMD, DSc, Head of the Cell Therapy Development Department; Federal Center of Brain Research and Neurotechnologies of the Federal Medical Biological Agency of Russia, 1, Bldg. 10, Ostrovityanova St., Moscow, 117513, Russia; Head of the Biomedical Research Center; Federal Scientific and Clinical Center for Specialized Types of Medical Care and Medical Technologies of the Federal Medical Biological Agency of Russia, 28 Orekhovy Blvd., Moscow, 115682, Russia; Head of the Laboratory of Molecular Regeneration Mechanisms; Engelhardt Institute of Molecular Biology of the Russian Academy of Sciences, 32 Vavilov St., Moscow, 119991, Russia; Head of the Regenerative Medicine Laboratory; Pulmonology Scientific Research Institute of the Federal Medical Biological Agency of Russia, 28 Orekhovy Blvd., 115682, Russia.
G M YusubalievaMD, PhD, Head of the Laboratory of Solid Tumor Immunotherapy; Federal Center of Brain Research and Neurotechnologies of the Federal Medical Biological Agency of Russia, 1, Bldg. 10, Ostrovityanova St., Moscow, 117513, Russia; Senior Researcher, Laboratory of Cell Technologies; Federal Scientific and Clinical Center for Specialized Types of Medical Care and Medical Technologies of the Federal Medical Biological Agency of Russia, 28 Orekhovy Blvd., Moscow, 115682, Russia; Senior Researcher, Laboratory of Molecular Regeneration Mechanisms; Engelhardt Institute of Molecular Biology of the Russian Academy of Sciences, 32 Vavilov St., Moscow, 119991, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma is the most aggressive primary brain tumor with poor prognosis characterized by resistance to standard treatments and immune evasion. Regulatory T lymphocytes (Tregs) play a key role in immune suppression in the tumor microenvironment and can be used as targets for malignant gliomas therapy. Materials and Methods: The study was performed using the C57Bl/6-FoxP3-eGFP mouse strain, which allows for the detection of FoxP3-positive Tregs by fluorescent signal. Orthotopic glioblastomas were implanted by stereotactic injection of fluorescently labeled GL-261-BFP and GL-261-mScarlet tumor cell lines. Intravital confocal microscopy was used to monitor infiltration of the tumor site by immune cells, visualized by intravenous injection of fluorescently labeled antibodies against CD45. The results of intravital microscopy were confirmed by histological and immunohistochemical examination on days 3, 6, 9, 14, and 16 after the implantation. To assess the immunological status, tumor-infiltrating lymphocytes (TILs) were isolated from the brain and Tregs were counted using a flow cytometer (immediately after isolation and after cultivation for 2 weeks). Results: Intravital microscopy and brain slice studies have demonstrated infiltration of the glioblastoma site by Tregs, with the proportion of Tregs increasing with tumor progression (the increase in the absolute number of Treg was proportional to the increase in the number of glioma cells). Subsequent co-cultivation of isolated TILs with glioma cells revealed increase of Treg population within 2 weeks from 2.8% to >40%, confirming the activating effect of glioblastoma with respect to Tregs. Conclusion: The dynamics of GL-261 glioma microenvironment infiltration by Tregs has been investigated. The glioblastoma cells were shown to activate Tregs in the peritumor space

Indexed as

Brain NeoplasmsCell MovementGlioblastomaT-Lymphocytes, RegulatoryTumor MicroenvironmentAnimalsCell Line, TumorDisease Models, AnimalLymphocytes, Tumor-InfiltratingMiceMice, Inbred C57BLMice, Transgenicglioblastomagliomamigrationregulatory T lymphocytestumortumor microenvironment

Identifiers

PMID40071070
PMCPMC11892569

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.